Registro basal: registro basal — English translation – Linguee

Registro basal: registro basal — English translation – Linguee

registro basal — English translation – Linguee





























Orientacin


[…]
general ( se realiza un registro basal para conocer las situaciones […]

problemticas).

tolerance-spinning.org

tolerance-spinning.org


General orientation (where a basal register is done in order […]

to know the problematic situations).

tolerance-spinning.org

tolerance-spinning.org

Tambin son factores contribuyentes la diabetes


[…]
[…]
gestacional (diabetes que aparece durante el embarazo), los trastornos de la tolerancia a la glucosa y las alteraciones de la glucemia basal.

eur-lex. europa.eu

eur-lex.europa.eu


Other contributory factors include gestational diabetes (diabetes during pregnancy), impaired glucose tolerance or impaired fasting glycaemia.

eur-lex.europa.eu

eur-lex.europa.eu

El tegumento de la larva de la mosca


[…]

domstica consiste de una cutcula exterior acelular y de una capa nica epitelial interior que


[…]
reposa sobre una membrana basal.

flycontrol.novartis.com

flycontrol.novartis.com

The integument of the house fly


[…]

larva consists of an outer acellular cuticle and an inner single layer of epithelium which


[…]
rests on a basement membrane.

flycontrol.novartis.co.uk

flycontrol.novartis.co.uk


La membrana basal glomerular es […]

una parte de los riones que ayuda a filtrar los desechos y lquido extra de la sangre.

missionhospitals.org

missionhospitals.org

Glomerular basement membrane is […]

a part of the kidneys that helps filter waste and extra fluid from the blood.

missionhospitals.org

missionhospitals.org

La falta


[…]
de inscripcin en el registro civil sigue obstaculizando […]

su acceso a los derechos sociales y econmicos bsicos.

eur-lex.europa.eu

eur-lex.europa.eu


The lack of civil registration continues to hinder [. ..]

their access to basic social and economic rights.

eur-lex.europa.eu

eur-lex.europa.eu

Espere un email de confirmacin, que llegar en


[…]
2-3 minutos, Confirme su registro siguiendo las instrucciones […]

del email.

securityspace.com

securityspace.com

Wait for a confirmation email, arriving in 2-3


[…]
minutes, Confirm your registration by following the email […]

instructions.

securityspace.com

securityspace.com

Puede aumentar


[…]
la tasa metablica basal, al igual que reducir […]

el apetito y la grasa corporal.

missionhospitals.org

missionhospitals.org


It can increase basal metabolic rate, and […]

reduce appetite and body fat.

missionhospitals.org

missionhospitals.org

En este estudio, el VPH se relacion con el carcinoma de clulas escamosas, pero no con el


[…]
carcinoma celular basal que es ms prevalente.

womenshealth.gov

womenshealth.gov

In this study, HPV was linked with squamous cell carcinoma but not its


[…]
more prevalent sister, basal cell carcinoma.

womenshealth.gov

womenshealth.gov

Las neuronas


[. ..]
conectadas al extremo basal, que normalmente tendran […]

CF alta, no responden.

interacoustics.com

interacoustics.com


Neurons connected to the basal end, that would normally […]

have high CFs, will not respond.

interacoustics.com

interacoustics.com


El carcinoma de clula basal es la forma ms […]

comn de cncer cutneo.

scasouthjersey.com

scasouthjersey.com

Basal cell carcinoma is the most […]

common form of skin cancer.

scasouthjersey.com

scasouthjersey.com

Las causas de distona, la mayor condicin, han sido relacionadas con el dao a una


[. ..]
parte del cerebro llamada ganglio basal.

scasouthjersey.com

scasouthjersey.com

Causes of dystonia, the greater condition, have been linked to damage to a part of


[…]
the brain called the basal ganglia.

scasouthjersey.com

scasouthjersey.com

aumenta la


[…]
tasa metablica basal, que es un requisito […]

importante para perder peso

eufic.org

eufic.org


the basal metabolic rate increases, […]

an important requirement for losing weight

eufic.org

eufic.org

Rellenar la parte interna


[. ..]
de las coronas o cara basal, seguidamente aplicar […]

SR Adoro Thermo Guard en las superficies expuestas


[…]

de metal, como festones, superficies oclusales y bordes marginales.

ivoclarvivadent.co

ivoclarvivadent.co

Rapidly fill up first the


[…]
internal aspects, or basal surfaces, of the crown […]

and then cover exposed metal parts, such as


[…]

scallops, occlusal surfaces and margins and smooth out SR Adoro Thermo Guard.

ivoclarvivadent.com

ivoclarvivadent.com

2.4 Los autores interpusieron un recurso de amparo ante el Tribunal Constitucional, denunciando la vulneracin del derecho a


[. ..]

la presuncin de inocencia por nulidad de


[…]
la entrada y registro domiciliario […]

y por falta de prueba sobre el carcter estupefaciente


[…]

de la sustancia objeto del trfico.

daccess-ods.un.org

daccess-ods.un.org

2.4 The authors submitted an application for amparo to the Constitutional Court, claiming a violation of the


[…]

right to be presumed innocent, on the grounds


[…]
that the house search had been invalid […]

and that there was no evidence that the


[…]

trafficked substance was a narcotic.

daccess-ods.un.org

daccess-ods. un.org

Dicho Tribunal es


[…]
responsable del registro civil de las personas […]

y de la emisin del documento de identidad personal.

daccess-ods.un.org

daccess-ods.un.org


It also maintained the civil registry and issued identity […]

documents.

daccess-ods.un.org

daccess-ods.un.org

Los mtodos acsticos no pueden


[…]
establecer el estado basal de los tubos; slo […]

pueden determinar qu tubos se estn deteriorando rpidamente.

ppic.com

ppic.com

Acoustic methods cannot establish


[. ..]
the baseline condition of the pipes; […]

they can only determine which pipes are actively deteriorating.

ppic.com

ppic.com


Clculo del metabolismo basal + metabolismo activo en kcal

wellnessproducts.ch

wellnessproducts.ch


Calculation of basic metabolic rate + active metabolic rate in kcal

wellnessproducts.ch

wellnessproducts.ch


La capa basal es la capa ms profunda de la epidermis y contiene clulas basales.

content.jeffersonhospital.org

content.jeffersonhospital.org


The basal layer is the deepest layer of the epidermis, containing basal cells.

content.jeffersonhospital.org

content.jeffersonhospital.org

Entre los receptores olfatorios se


[…]

cuentan sensilas situadas en varias fosetas localizadas


[…]
ventralmente sobre el tercio basal del tercer segmento […]

de la antena.

flycontrol.novartis.com

flycontrol.novartis.com

Among the olfactory receptors are sensilla located in several pits which


[…]
lie ventrally on the basal one-third of the third […]

segment of the antenna.

flycontrol.novartis.co.uk

flycontrol.novartis.co.uk


La temperatura basal es la temperatura que se registra despus de haber descansado, [. ..]

es decir antes de levantarse o emprender cualquier actividad.

raxmedical.com

raxmedical.com


The basal body temperature is the temperature of the body just after waking up, […]

before getting up and before becoming active in any way.

raxmedical.com

raxmedical.com


El carcinoma de clulas basales aparece por lo […]

general en forma de bulto elevado o de lesin ulcerada, comnmente en reas de exposicin previa al sol.

moffitt.org

moffitt.org

Basal cell carcinoma generally appears […]

as a raised lump or ulcerated lesion, usually in areas with previous sun exposure.

moffitt.org

moffitt.org

En zonas despobladas de vegetacin se instalan


[…]

empalizadas de varas de mimbre seco, hincadas verticalmente en el suelo con


[…]
los extremos basales de las ramas […]

hacia abajo.

fccconstruccion.com

fccconstruccion.com

In areas without plants, sand traps are


[…]
installed that consist of fences of dry […]

reeds set vertically in the sand with their branches upwards.

fccconstruccion.com

fccconstruccion.com

Esta informacin ser utilizada para


[…]

completar la evaluacin geolgica del pozo a nivel del intervalo de C7 y


[. ..]
de la Unidad Arenas Basales (Formacin Mirador).

pacificrubiales.com

pacificrubiales.com

The resulting data will be used to complete the geological evaluation of the


[…]
C7 interval and the Basal Sandstones (Mirador Formation).

pacificrubiales.com

pacificrubiales.com

El melanoma es un tipo de cncer ms grave que los


[…]
cnceres de clulas basales o escamosas, que son […]

ms frecuentes.

content.jeffersonhospital.org

content.jeffersonhospital.org

Melanoma is a more serious type of cancer


[…]
than the more common basal cell cancer, or squamous [. ..]

cell cancer.

content.jeffersonhospital.org

content.jeffersonhospital.org


Las clulas basales y las escamosas […]

son los dos tipos ms comunes.

perimetersurgerycenter.com

perimetersurgerycenter.com

Basal cell and squamous cell are […]

the two most common.

perimetersurgerycenter.com

perimetersurgerycenter.com

Este cncer, que responde excelentemente al tratamiento, se gesta en


[…]
la capa de clulas basales de la epidermis (la […]

capa cutnea superior) y crece con mucha lentitud.

healthlibrary.b…amandwomens.org

healthlibrary.b. ..amandwomens.org

This highly treatable


[…]
cancer starts in the basal cell layer of the epidermis […]

(the top layer of skin) and grows very slowly.

healthlibrary.b…amandwomens.org

healthlibrary.b…amandwomens.org

Recibe su


[…]
nombre de las clulas basales, que se encuentran […]

en la base de la capa externa de la piel.

scasouthjersey.com

scasouthjersey.com


It is named for basal cells, which lie at […]

the base of the outer layer of skin.

scasouthjersey.com

scasouthjersey.com

La magnitud de la respuesta de los parmetros fisiolgicos har


[. ..]
referencia a niveles basales y extremos as como […]

al factor tiempo.

eur-lex.europa.eu

eur-lex.europa.eu

The magnitude of response of the physiological


[…]
parameters will refer to basal and extreme levels and […]

time dependency.

eur-lex.europa.eu

eur-lex.europa.eu

Basal body temperature for natural family planning

Overview

The basal body temperature method — a fertility awareness-based method — is a type of natural family planning. Your basal body temperature is your temperature when you’re fully at rest. Ovulation may cause a slight increase in basal body temperature.

You’ll be most fertile during the two to three days before your temperature rises. By tracking your basal body temperature each day, you may be able to predict when you’ll ovulate. This may help you determine when you’re most likely to conceive.

If you’re hoping to get pregnant, you can use the basal body temperature method to determine the best days to have sex. Similarly, if you’re hoping to avoid pregnancy, you can use the basal body temperature method to figure out which days to avoid unprotected sex.

The basal body temperature method alone may not provide enough warning time to effectively prevent pregnancy. Often, people use this method in combination with other fertility awareness-based methods for avoiding pregnancy.

Products & Services

  • Book: Mayo Clinic Guide to a Healthy Pregnancy
  • Book: Mayo Clinic Guide to Fertility and Conception
  • Book: Your Sexual Health

Why it’s done

Basal body temperature can be used as a way to predict fertility or as a part of a method of contraception, by helping you gauge the best days to have or avoid unprotected sex.

Tracking your basal body temperature for either fertility or contraception is inexpensive and doesn’t have any side effects. Some women may choose to use the basal body temperature method for religious reasons.

The basal body temperature method can also be used to detect pregnancy. Following ovulation, a rise in basal body temperature that lasts for 18 or more days may be an early indicator of pregnancy.

The basal body temperature method is often combined with the cervical mucus method of natural family planning, where you keep track of cervical secretions throughout the course of a menstrual cycle. You might also use an electronic fertility monitor to measure hormone levels in your urine, which can tell you which days you’re fertile. This combination of approaches is sometimes referred to as the symptothermal or symptohormonal method.

Request an Appointment at Mayo Clinic

Risks

Using the basal body temperature method to promote fertility doesn’t pose any risks.

Likewise, using the basal body temperature method for birth control doesn’t pose any direct risks, but it doesn’t offer protection from sexually transmitted infections — and it’s one of the least effective natural family planning methods. As many as 1 in 4 women — maybe even more — who use fertility awareness-based methods to prevent pregnancy will become pregnant after one year of typical use.

Using the basal body temperature method along with another fertility awareness-based method for birth control may improve the method’s effectiveness. But, the method requires motivation and diligence. If you don’t want to conceive, you and your partner must avoid having sex or use a barrier method of contraception during your fertile days each month.

How you prepare

Tracking your basal body temperature doesn’t require special preparation. However, if you want to use the basal body temperature along with another fertility awareness-based method for birth control, consult your health care provider first if:

  • You recently gave birth or stopped taking birth control pills or other hormonal contraceptives
  • You’re breast-feeding
  • You’re approaching menopause

Keep in mind that your basal body temperature can be influenced by many factors, including:

  • Illness or fever
  • Stress
  • Shift work
  • Interrupted sleep cycles or oversleeping
  • Alcohol
  • Travel and time zone differences
  • Gynecologic disorders
  • Certain medications

What you can expect

To use the basal body temperature method:

  • Take your basal body temperature every morning before getting out of bed. Use a digital oral thermometer or one specifically designed to measure basal body temperature. Make sure you get at least three hours of uninterrupted sleep each night to ensure an accurate reading.

    For the most accurate results, always take your temperature using the same method. Try to take your temperature at the same time each day, when you first wake up.

  • Track your temperature readings. Record your daily basal body temperature and look for a pattern to emerge. You can do this on a paper chart or an app designed for this purpose.

    Basal body temperature may increase slightly — typically less than a 1/2 degree F (0.3 C) — when you ovulate. Ovulation has likely occurred when the slightly higher temperature remains steady for three days or more.

  • Plan sex carefully during fertile days. You’re most fertile about two days before your basal body temperature rises, but sperm can live up to five days in your reproductive tract.

    If you’re hoping to get pregnant, this is the time to have sex. If you’re hoping to avoid pregnancy, unprotected sex is off-limits from the start of your menstrual period until three to four days after your basal body temperature rises — every month.

Although there are numerous apps available for tracking menstrual cycles, only one is approved by the U.S. Food and Drug Administration (FDA) for pregnancy prevention.

Natural Cycles uses an algorithm to calculate the days during your cycle when you’re more likely to be fertile. The app calculates your fertile days based on daily temperature readings as well as other information you input about your menstrual cycle.

By Mayo Clinic Staff

Related

Products & Services

Insulin therapy. New realities — «InfoMedPharmDialogue»

Skip to content

insulin therapy. New realities

Insulin therapy. New realities

The annual mortality from diabetes in the world exceeds the combined mortality from HIV, tuberculosis and malaria. Despite great efforts to achieve and maintain optimal glycemic control, we are still losing the war against type 2 diabetes. This opinion was expressed by Professor A.S. Ametov at the plenary session «Insulin Therapy: New Realities 2020». During the event, experts discussed the possibilities of optimizing therapy with basal insulin analogs and combined injectables.

A war that can be won

A.S. AMETOV

Head of the Department of Endocrinology and Diabetology, RMANPE of the Ministry of Health of Russia, Professor, MD A.S. Ametov noted that five million people die from diabetes every year in the world. In total, this is more than from infectious diseases: 1.5 million people die from HIV and tuberculosis, 0.6 million from malaria. , said the professor.

Type 2 diabetes develops slowly and insidiously, metabolic disorders occur, including a progressive decrease in the mass of functioning beta cells. Insulin secretion falls, beta cells lose sensitivity, followed by impaired glucose tolerance and diabetes develops.

It is very important immediately after diagnosis to begin not only control, but also the management of glycemia. In type 2 diabetes, attention is focused on two key points in the regulation of glucose homeostasis: adequate secretion of insulin by beta cells and the ability of peripheral tissues to respond to insulin.

“When managing glycemia, how far do you go to lower glycated hemoglobin? What treatment should be prescribed to a patient after metformin with a glycated hemoglobin level of 8% or more? — Professor A.S. asked a question. Ametov, to which he immediately answered. “If the goal is to reduce the level of glycated hemoglobin, all existing classes of hypoglycemic drugs can be used, but when choosing a treatment regimen, a personalized approach should be practiced, taking into account the characteristics of the course of diabetes in a particular patient.”

The need for an individual approach to the treatment of a patient with DM2 Professor A.S. Ametov illustrated on the example of four clinical cases, where the level of glycated hemoglobin in patients was similar — 7. 7%, and the daily variability of glycemia was very different. “Do patients need the same therapy? No. These are four different cases,” he said.

The main «player» in ensuring glucose homeostasis

The main «player» in ensuring glucose homeostasis is insulin. The hormone triggers the expression of more than 100 different genes, and therefore its meaning should not be interpreted primitively, emphasized Professor A.S. Ametov.

“Insulin therapy for type 2 diabetes mellitus is about overcoming insulin resistance at the level of the liver, kidneys and other tissues, and not a variant of hormone replacement therapy,” said the professor. “We are talking about replacement therapy only in the late stages of type 2 diabetes.”

The goal of administering basal insulin to patients with type 2 diabetes is to maintain a constant level of insulin between meals, which minimizes the risk of hypoglycemia, especially at night. At the same time, the dose of basal insulin is selected based on the level of fasting glycemia, and not the indicator of glycated hemoglobin, the speaker specified.

An ideal basis for rational combinations

Professor Ametov, referring to the results of a study on the distribution of insulin concentration and glucose dynamics per fluctuation during the day, authored by prof. Becker R.H., where glargine-300 was administered as basal insulin to patients, identified the main advantage of using basal insulin in T2DM.

“Using insulin glargine-300 as an example, a uniform distribution of the glucose-lowering effect was demonstrated throughout the day. In fact, there were no conditions for hypo- or hyperglycemia,” he said.

Speaking about cardiac safety, which was also studied in the study, the speaker noted an improvement in endothelial function in type 2 diabetes mellitus during insulin glargine-300 therapy. At the same time, the early addition of basal insulin to treatment regimens for type 2 diabetes during follow-up of patients for six years revealed a neutral effect on the cardiovascular system, it does not accelerate, and possibly even slows down the progression of atherosclerosis.

“Basal insulin is the ideal foundation for any rational combination with hypoglycemic agents. We get good metabolic control,” concluded the professor.

From research to real clinical practice

The need for insulin in T2DM is dictated by different clinical situations, said the head of the Department of Endocrinology of the Russian National Research Medical University. N.I. Pirogova, professor, d.m.s. T.Yu. Demidov. This may be genetically determined diabetes, and a situation where the need for intensification of therapy is associated with poor glycemic control or a decrease in the secretory potential of beta cells.

“Today we are looking for possible ways to modify the mechanisms that underlie type 2 diabetes. Glycemic control is the only predictor of a favorable or unfavorable metabolic, cardiovascular and renal prognosis. Good control improves long-term results,” the speaker clarified. Early achievement of glycemic targets is the key to effective diabetes management.

Russia was included in the IDMPS 8 program, which assessed the level of glycemic control in patients living in different countries. On average, the proportion of patients who participated in the program who achieved an individual target value of glycated hemoglobin was at the level of 49.8%.

According to the dynamic monitoring of HbA1c, in seven regions of Russia, its indicators were close to 9%. This is exactly the situation when it is necessary to initiate the transition to insulin therapy, Professor Demidova commented on the results of the study. 9T.Yu. Demidova spoke about the results of a meta-analysis by Morten Hasselstrom, which assessed the risks of cardiovascular events, severe hypoglycemia and mortality from all causes when using several combinations of oral and injectable antidiabetic drugs.

The combination of basal insulin and GLP-1 receptor agonists (arGLP-1) has been found to be significantly superior to oral antidiabetic drug combination options. A possible reason for T.Yu. Demidova called the modification of pathogenetic mechanisms when using a combination of insulin and arGLP-1.

T.Yu. DEMIDOVA

By the way, the same meta-analysis made the professional community think again about the role of sulfonylurea drugs in the treatment of patients with type 2 diabetes. As Professor Demidova noted, they should leave the practice.

«These drugs have served brilliantly for the past decades, today we have to put them aside — they do not provide any benefits other than lowering blood glucose,» she stressed.

Don’t wait, start…

A study by Professor J. Rosenstock, which analyzed data from real clinical practice and compared the effectiveness of simultaneous or sequential starting therapy with basal insulin and arGLP-1, partly answers the question, what is the optimal scheme for starting therapy for type 2 diabetes mellitus, explained Professor T.Yu. Demidov. Patients with HbA1c above 9% were included in the therapy intensification program. With the simultaneous administration of a combination of basal insulin and arGLP-1 as initial therapy, patients received the most significant benefits compared with groups where injectable drugs were administered sequentially: 45.3% achieved a glycated hemoglobin level of less than 7% by the sixth month of therapy (Fig. 1) .

“Don’t wait, start early. There is no need to think: the later, the better it will work, ”according to T.Yu. Demidova, a doctor should be guided by choosing a combination therapy regimen for a patient with high levels of glycated hemoglobin.

Clinical inertness through the lens of the registry

N.A. DEMIDOV

Chief freelance endocrinologist of the Troitsk and Novomoskovsk Autonomous Regions of Moscow, Ph.D. ON THE. Demidov, presenting data from the Federal Diabetes Registry from 2016 to 2019.

Oral hypoglycemic drugs form the basis of type 2 diabetes therapy in Moscow. Insulin is used by about 20% of patients. The number of patients taking innovative drugs is growing, almost every fifth patient receives them.

In recent years, there has been an unusual trend: the proportion of patients with type 2 diabetes on insulin has risen to 22%. However, this figure dropped in 2019. ON THE. Demidov connected this phenomenon with the appearance of new classes of oral hypoglycemic drugs in the arsenal of endocrinologists, which somewhat postponed the start of insulin therapy. The proportion of patients with type 2 diabetes receiving insulin analogues is growing, reaching 72% in 2020. In the prescriptions of basal insulins, glargine is the leader (this is 53% of patients), prandial — aspart (37.6%).

At the same time, against the background of a general decrease in insulin consumption in the group of patients with type 2 diabetes, the number of prescriptions of glargine as a basal analogue increases (Fig. 2).

Almost half of the Moscow dispensary group was on monotherapy in 2019 – 144 thousand patients. And in 60% of cases, it was possible to achieve a level of glycated hemoglobin below 7%. It is curious that the intensification of therapy, the inclusion of a second drug in it, led to the opposite situation — in 60% of cases, the goal could not be achieved. A further increase in the number of drugs in the combination did not practically change the picture. Why? ON THE. Demidov explained this by the late intensification of therapy, when the inclusion of the second, and then the third drug, including insulin, no longer has the effect that could be expected with a timely appointment.

For example, when initiating basal insulin (more than 18,000 people according to 2019 data), HbA1c below 7% was achieved in only 22% of patients.

“The increase in therapeutic activity does not lead to anything. We linger for a long time at each stage,” the speaker complained. – Each subsequent step lags behind in time. At every step, we lose control.»

Another serious problem is errors in titration of insulin doses. As a result, even with the intensification of therapy and the appointment of insulin, the expected results cannot be achieved. Simply because the recommended doses of insulin are very far from those that can bring glycemia closer to the target values. Thus, according to the registry data, 40% of patients with type 2 diabetes in Moscow receive only 11–20 units of insulin two years after the start of insulin therapy, and 13% receive less than 10 units!

“Today, a good option has appeared to intensify the injection therapy of patients with DM2 — to add a ready-made combination of insulin with arGLP-1,” noted N.A. Demidov. According to the registry, in 2019, 4% of patients with type 2 diabetes started treatment using this regimen. In 11 months of 2020, 11% of patients switched to it (Fig. 3). At the same time, the speaker emphasized, it is necessary to resolve an important issue — to clearly define who should “start” with basal insulin, and who should immediately be shown the combination of insulin plus arGLP-1. At the same time, new opportunities that open up for the doctor and the patient with the arrival of innovative drugs on the market should not run into such a serious and, unfortunately, insurmountable obstacle as the clinical inertia of the doctor.

Nataliya2021-05-17T15:37:20+03:00

Page load link

Go to Top

Basal insulin Tujeo SoloStar® approved in Russia

New basal insulin provides better glycemic control within 24 hours with less risk of hypoglycemia compared to
with Lantus [1] , [2], [3] , [4]

Moscow, July 12, 2016 – Sanofi announced that it has received a marketing authorization in Russia for Tujeo SoloStar® (insulin glargine 300 IU/mL), a long-acting basal insulin approved for use in the treatment of diabetes mellitus 1 and 2 types in adults [5] . The first batch of the new insulin is expected in Russia in September 2016.

According to the All-Russian epidemiological study NATION [6] , there are about 6 million patients with type 2 diabetes in Russia. More than 50% of patients do not reach the optimal level of glycemia [7] .

“For nearly a century, treatments for diabetes have been developed. Throughout this period, we have not only made progress in therapy, but also accumulated scientific data that open up new aspects of the disease and make treatment goals more ambitious. With the advent of an advanced diabetes drug, we have a tool that allows us to set more ambitious goals in the treatment of diabetes, which is aimed at improving the prognosis and quality of life of our patients. Today, this drug is Tujeo insulin, and we have the opportunity to apply its innovative properties in Russian clinical practice. According to existing data, Toujeo has advantages in terms of the incidence of hypoglycemia and body weight dynamics compared to Lantus insulin, and also maintains its heritage in terms of proven cardiovascular and oncological safety. We have accumulated a positive long-term experience in the use of insulin glargine 100 IU, today we have the opportunity to get acquainted with a new generation of glargine,” said Shestakova M.V., Corresponding Member of the Russian Academy of Sciences, Director of the Diabetes Institute of the FGBU ERC.

The registration of the new medicinal product is based on the results of the EDITION clinical trial program, which is a series of large international phase III studies evaluating the efficacy and safety of Toujeo compared with Lantus, in which more than 3500 patients participated. In studies, the new insulin showed comparable efficacy and a more favorable safety profile. Tujeo has been associated with a lower risk of hypoglycemia in people with diabetes. The new insulin also showed a more stable action profile and lower glycemic variability compared to Lantus over 24 hours and beyond 4 .

“The addition of a new basal insulin to the company’s portfolio marks an important milestone in Sanofi’s nearly century-old diabetes history. We continue to develop and bring to market new drugs to meet the needs of people with diabetes. Tujeo with a smoother and longer action profile, comparable efficacy to Lantus insulin and improved safety can help increase the number of patients who achieve their individual goals. We are not only bringing an innovative drug to the Russian market, but also as part of the Pharma 2020 we launch it into production at the Sanofi-Aventis Vostok plant, starting with secondary packaging already in 2016. It is planned to enter the full cycle in 2018,” commented Oksana Monzh, Head of the Endocrine Medicines Business Unit at Sanofi Russia, at .

About Tujeo

Tujeo represents the latest generation of long acting basal insulins. The drug contains a triple number of active substance units in 1 ml of solution (300 IU/ml), which significantly changes its properties5. Toujeo provides a slower release of insulin and its gradual entry into the bloodstream, as well as a long-term effect, which leads to reliable control of blood glucose levels for 24 hours and a lower risk of hypoglycemia compared to Lantus 9 preparations0103 1, 2, 3, 4 .

Tujeo is approved for use on 5 continents, in 34 countries, including EU Member States, Iceland, Liechtenstein, Norway, Japan and the USA.

About Sanofi

Sanofi is one of the world leaders in healthcare. The company develops and implements solutions aimed at meeting the needs of patients around the world. Sanofi has been operating in Russia for 45 years. The company’s staff in Russia has more than 2,000 people. Today, Sanofi occupies one of the leading positions in the Russian pharmaceutical market, offering its patients a wide range of original drugs and generics in key therapeutic areas such as diabetes, oncology, cardiovascular diseases, internal medicine, diseases of the central nervous system, vaccine prevention and rare diseases.

About the Sanofi-Aventis Vostok plant

In 2010, a high-tech production complex of CJSC Sanofi-Aventis Vostok was launched in the Oryol region. Currently, this is the first and only plant in Russia for the production of the most modern insulins in a full cycle. The production capacity of the plant is sufficient to meet the needs of the Russian and CIS markets for modern insulins. In July 2015, the Sanofi-Aventis Vostok plant successfully passed the European inspection and received a GMP certificate from the European Medicines Agency (EMA), which will allow the export of insulin produced in Orel to the countries of the European Union.

About diabetes

Diabetes is a severe chronic disease that continues to increase in prevalence throughout the world. In the world, more than 400 million people currently suffer from diabetes, and by 2040 their number, according to experts, will exceed 640 million [8] . That’s about 10 million new cases every year.

Data on the number of people with diabetes mellitus in Russia until recently were extremely limited due to the lack of large epidemiological studies, since the existing register of patients takes into account only diagnosed cases.

Thanks to Russia’s largest epidemiological study, NATION, objective data have been obtained for the first time on the real prevalence of type 2 diabetes mellitus in the Russian Federation, which is 5. 4%, that is, about 6 million people 6 . Of these, more than half do not know about their disease, and about 40% are in the stage of decompensation. Another 20% of the population are at risk because they have prediabetes. The NATION study was initiated by the Endocrinology Research Center within the framework of a memorandum signed between the ENTS and Sanofi Russia on February 28, 2013 in the Kremlin in the presence of the Presidents of Russia V. Putin and France F. Hollande.

Diabetes has a high economic cost. Worldwide, about 12% of the total healthcare budget is spent on diabetes [9] . Diabetes mellitus and its complications are one of the leading causes of disability and mortality in the population, including those of working age. Budget costs for patients who have developed complications of diabetes significantly exceed the costs for patients without complications. Timely diagnosis, as well as effective and safe therapy with modern drugs, including the latest generation of insulins, continues to be the key to controlling the economic burden of diabetes.

Contacts

Communications Sanofi Russia
+7 (495) 721-14-00
[email protected]

Press release

[1] Yki-Järvinen H, et al. Diabetes Care 2014; 37:3235-3243.

[2] Home P., et al. Diabetes Care 2015; 38:2217-2225.

[3] Ritzel, R. et al. Diabetes Obes. Metab. 2015; 17:859–867.

[4] Becker RH, et al. Diabetes Care 2015; 38(4): 637–643.

[5] Instructions for use Tujeo SoloStar®

[6] The study was initiated by the Endocrinology Research Center (ESC) of the Ministry of Health of the Russian Federation in partnership with Sanofi Russia to assess the real situation with type 2 diabetes in Russia in 2013-2014.

[7] Dedov I., et al. Prevalence of Type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Research and Clinical Practice 2016; 115:90-95.

[8] International Diabetes Federation. IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation, 2015.

Добавить комментарий

Ваш адрес email не будет опубликован. Обязательные поля помечены *